Incyte Management

Management Kriterienprüfungen 3/4

Incyte CEO ist Herve Hoppenot , ernannt in Jan 2014, hat eine Amtszeit von 10.83 Jahren. Die jährliche Gesamtvergütung beträgt $16.66M , bestehend aus 7.8% Gehalt und 92.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.2% der Aktien des Unternehmens, im Wert von MX$590.43M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 8.8 Jahre bzw. 7.8 Jahre.

Wichtige Informationen

Herve Hoppenot

Geschäftsführender

US$16.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.8%
Amtszeit als Geschäftsführer	10.8yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	8.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Herve Hoppenot im Vergleich zu den Einnahmen von Incyte verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$32m
Jun 30 2024	n/a	n/a	US$97m
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

Vergütung im Vergleich zum Markt: HerveDie Gesamtvergütung ($USD16.66M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt MX ($USD5.76M).

Entschädigung vs. Einkommen: HerveDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Herve Hoppenot (64 yo)

10.8yrs

Amtszeit

US$16,659,526

Vergütung

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Herve Hoppenot	CEO & Chairman	10.8yrs	US$16.66m	0.20% MX$ 590.4m
Pablo Cagnoni	President and Head of Research & Development	1.5yrs	US$16.57m	0.00087% MX$ 2.6m
Christiana Stamoulis	Executive VP & CFO	5.8yrs	US$5.08m	0.019% MX$ 57.1m
Barry Flannelly	Executive VP & GM of North America	9.4yrs	US$4.09m	0.0062% MX$ 18.5m
Steven Stein	Executive VP & Chief Medical Officer	9.7yrs	US$5.63m	0.0013% MX$ 4.0m
Thomas Tray	VP of Finance	2.7yrs	keine Daten	0.0047% MX$ 14.0m
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.8yrs	keine Daten	0.019% MX$ 56.0m
Ben Strain	Head of Investor Relations	no data	keine Daten	keine Daten
Sheila Denton	Executive VP	1.1yrs	keine Daten	0.0023% MX$ 6.9m
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	keine Daten	keine Daten
Paula Swain	Executive Vice President of Human Resources	22.3yrs	US$1.31m	0.030% MX$ 89.5m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0044% MX$ 13.1m

8.8yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: INCY *Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Herve Hoppenot	CEO & Chairman	10.8yrs	US$16.66m	0.20% MX$ 590.4m
Jean-Jacques Bienaime	Independent Director	9.8yrs	US$478.76k	0.0080% MX$ 23.9m
Julian Baker	Independent Lead Director	23yrs	US$512.76k	0.14% MX$ 430.9m
Otis Brawley	Independent Director	3.2yrs	US$454.76k	0.0031% MX$ 9.1m
Jacqualyn Fouse	Independent Director	7.8yrs	US$466.26k	0.0073% MX$ 21.6m
Edmund Harrigan	Independent Director	4.9yrs	US$482.26k	0.0072% MX$ 21.5m
Katherine High	Independent Director	4.7yrs	US$454.76k	0.0042% MX$ 12.4m
Paul Clancy	Independent Director	9.8yrs	US$479.76k	0.0086% MX$ 25.6m
Susanne Schaffert	Independent Director	2.1yrs	US$444.76k	0.0015% MX$ 4.5m

7.8yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: INCY *Die Vorstandsmitglieder gelten als erfahren (7.8 Jahre durchschnittliche Amtszeit).

Incyte Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Insufficient new directors

Insider recently sold Mex$10m worth of stock

Executive VP & Chief Medical Officer recently sold Mex$13m worth of stock

Executive VP of Global Medical Affairs recently sold Mex$20m worth of stock

Executive VP & GM of North America recently sold Mex$1.5m worth of stock

Recent updates

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Insufficient new directors

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Insufficient new directors

Insider recently sold Mex$10m worth of stock

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold Mex$13m worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023)

Executive VP of Global Medical Affairs recently sold Mex$20m worth of stock

Executive VP & GM of North America recently sold Mex$1.5m worth of stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

VP of Finance recently sold Mex$1.1m worth of stock

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation Provides Earnings Guidance for 2024

New minor risk - Profit margin trend

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults

Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation

Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma